Aclaris Therapeutics, Inc. (ACRS) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
ACRS currently has 129M outstanding shares. with significant dilution risk as 190M authorized shares could dilute existing holders by 147.6%. The company has significantly diluted shareholders by 79.05% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 07, 2026 |
10-Q filing | 128.8M shares outstanding |
130M | 190M |
| Nov 06, 2025 |
10-Q filing | 108.3M shares outstanding |
110M | 210M |
| Aug 07, 2025 |
10-Q filing | 108.3M shares outstanding |
110M | 210M |
| May 08, 2025 |
10-Q filing | 108.3M shares outstanding |
110M | 210M |
| Feb 27, 2025 |
S-3 filing: Aclaris Therapeutics, Inc. files an S-3 registration statement to offer and sell up to $300,000,000 of common stock, preferred stock, debt securities, and/or warrants from time to time. |
71M | 250M |
| Feb 27, 2025 |
10-K filing | 77.3M shares outstanding |
77M | 240M |
| Dec 19, 2024 |
S-3 filing: This is an S-3 filing for the offer and resale of up to 35,555,555 shares of common stock by selling stockholders. |
71M | 100M |
| Nov 18, 2024 |
8-K filing: Aclaris Therapeutics, Inc. entered into an exclusive license agreement with Biosion, Inc. and a collaboration agreement with Biosion and Chia Tai Tianqing Pharmaceutical Group, Co., Ltd. In connection with the agreements, Aclaris issued warrants to purchase 14,281,985 shares of common stock and sold 35,555,555 shares of common stock to accredited investors in a private placement for gross proceeds of approximately $80.0 million. ($80.0M proceeds) |
71M | 66M |
| Nov 06, 2024 |
10-Q filing | 71.4M shares outstanding |
71M | 66M |
| Aug 07, 2024 |
10-Q filing | 71.3M shares outstanding |
71M | 66M |
| May 07, 2024 |
10-Q filing | 71.1M shares outstanding |
71M | 67M |
| Feb 27, 2024 |
10-K filing | 69.8M shares outstanding |
70M | 68M |
| Nov 06, 2023 |
10-Q filing | 70.8M shares outstanding |
71M | 67M |
| Aug 07, 2023 |
10-Q filing | 70.6M shares outstanding |
71M | 67M |
| May 08, 2023 |
10-Q filing | 66.9M shares outstanding |
67M | 71M |
| Feb 23, 2023 |
10-K filing | 65.2M shares outstanding |
65M | 72M |
| Nov 08, 2022 |
10-Q filing | 66.7M shares outstanding |
67M | 71M |
| Aug 03, 2022 |
10-Q filing | 66.0M shares outstanding |
66M | 72M |
| May 10, 2022 |
10-Q filing | 61.4M shares outstanding |
61M | 76M |
| Feb 24, 2022 |
10-K filing | 56.7M shares outstanding |
57M | 81M |
| Nov 02, 2021 |
10-Q filing | 61.2M shares outstanding |
61M | 76M |
| Aug 05, 2021 |
10-Q filing | 61.2M shares outstanding |
61M | 76M |
| Jun 11, 2021 |
8-K filing: Aclaris Therapeutics, Inc. entered into an underwriting agreement to issue and sell 7,042,254 shares of common stock in a public offering at $17.75 per share, with the underwriters having an option to purchase an additional 1,056,338 shares. ($117.3M proceeds) |
52M | 86M |
| May 07, 2021 |
10-Q filing | 52.1M shares outstanding |
52M | 86M |
| Feb 25, 2021 |
10-K filing | 45.1M shares outstanding |
45M | 93M |
| Jan 22, 2021 |
8-K filing: Aclaris Therapeutics, Inc. entered into an underwriting agreement to issue and sell 5,483,714 shares of common stock at $17.50 per share, with the underwriters purchasing the shares at $16.45 per share, resulting in estimated net proceeds of $90.0 million, with the offering expected to close on January 22, 2021. ($95.97M proceeds) |
43M | 95M |
| Nov 04, 2020 |
10-Q filing | 42.9M shares outstanding |
43M | 95M |
| Aug 07, 2020 |
10-Q filing | 42.7M shares outstanding |
43M | 95M |
| May 07, 2020 |
10-Q filing | 41.9M shares outstanding |
42M | 96M |
| Mar 13, 2020 |
S-3 filing: The filing is an S-3 registration statement for a shelf offering of common stock with an aggregate offering price of up to $25.0 million through Jefferies and also indicates that the company may offer up to $100,000,000 of any combination of common stock, preferred stock and debt securities. |
42M | 96M |
| Feb 25, 2020 |
10-K filing | 41.5M shares outstanding |
42M | 0 |